Scroll to top

Scroll to top

News Releases

News Releases

Month Year

Month Year

Investor Alerts

Aug 2, 2020

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

- Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis -
Jul 30, 2020

Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Jul 29, 2020

Immunic, Inc. to Participate in Investor Conferences in August
Jul 27, 2020

Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19

- Study Being Conducted in Collaboration with University Hospitals Coventry and Warwickshire NHS Trust -
Jun 22, 2020

Immunic, Inc. to Join Russell 3000® Index
Jun 15, 2020

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
Jun 10, 2020

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
Jun 9, 2020

Immunic, Inc. Announces Proposed Public Offering of Common Stock
Jun 9, 2020

Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
May 29, 2020

Immunic, Inc. to Participate in Investor and Industry Conferences in June

Show per page